Science

Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

Data Presented at AACR-NCI-EORTC International Conference EAGAN, MN — October 30, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy Imprime PGG activates Natural Killer (NK) cell-mediated killing of cancer cells. The data were presented at the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, taking...

Read More


Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Researchers to Present Preclinical Data at EORTC-NCI-AACR Symposium EAGAN, MN — November 29, 2016 — Biothera Pharmaceuticals, Inc. will present data tomorrow illustrating the unique cytokine response generated by its phase 2 cancer immunotherapy Imprime PGG, the only Pathogen Associated Molecular Patterning (PAMP) molecule that has been successfully administered systemically. The data will be highlighted in two poster presentations at the 28th EORTC-NCI-AACR Symposium on Molecular...

Read More


MIT Research: Targeting Both Innate and Adaptive Immunity may be the Key to Enhancing the Effectiveness of Cancer immunotherapy

Last week scientists at the Massachusetts Institute of Technology provided compelling new preclinical research that large, aggressive tumors in mice could be eradicated by combining a series of immune therapies to activate both the innate and adaptive immune systems. Immunologic rejection of these large, advanced tumors was achieved through an orchestrated immune attack triggered by the rational combination of immune-modulatory agents, each of which was...

Read More


Biothera’s Investigational Cancer Immunotherapy Imprime PGG Neutralizes Cancer Defense Mechanisms in the Tumor Microenvironment

New Preclinical Data to be presented today at Keystone Symposium in Montreal EAGAN, MN, March 9, 2015 — New preclinical research from Biothera further demonstrates the ability of its cancer immunotherapy drug candidate Imprime PGG® to initiate a cascade effect of immune responses that neutralize cancer-associated immunosuppression in the tumor microenvironment. Biothera will present the new data today in Montreal at the Keystone Symposium: Dendritic...

Read More